Patient Acquisition Cost Trend: What Your CAC Snapshot Hides
Part 1 of 7 — The Patient Marketing Diligence (PMD) Framework
A healthcare practice can hand you a clean cost-per-patient number and still be hiding a patient acquisition cost trend that’s about to become your problem, not theirs.
That’s the uncomfortable truth behind Dimension 1 of the Patient Marketing Diligence framework: Acquisition Efficiency & Trend. It sounds like the most basic thing to check in a diligence process, since CAC and CPL are numbers every practice already tracks. But a single-period cost figure tells you almost nothing on its own. What actually matters is the patient acquisition cost trend behind it, and whether that trend has been quietly managed in the months before the data room opened.
Why a Snapshot Isn't a Trend
Ask a target for their cost per patient acquired, and you’ll usually get one number, for one recent period. It might genuinely be a good number. But a good number in isolation can’t tell you whether the account is getting more efficient, holding steady, or slowly eroding while volume is propped up by other means.
This matters because a rising or falling patient acquisition cost trend tells a very different story than a single data point ever could. A practice with a $220 CPL that’s been flat for two years is a fundamentally different asset than a practice with the same $220 CPL that was $150 eighteen months ago. Same number, opposite trajectory, and only one of them is a business you’d want to underwrite a growth multiple on.
The Trap: Efficiency Propped Up by Spend Cuts
Here’s the pattern worth watching for specifically. A seller preparing for a sale has every incentive to make trailing marketing metrics look clean. One of the easiest ways to do that isn’t to actually improve efficiency, it’s to quietly reduce ad spend and let volume drop along with it. CAC can look stable or even improve, while the practice is simply buying fewer patients.
This is why Dimension 1 isn’t scored on CAC alone. It’s scored on the relationship between cost, spend, and volume over a full 24-month window. If cost per patient looks flat but total spend has also been declining, that’s not a healthy patient acquisition cost trend. That’s a shrinking acquisition engine dressed up to look calm.
How to Actually Pull the Trend
The good news is this dimension doesn’t require anything exotic. In Google Ads, segment by month across a trailing 24-month window and pull Cost and Conversions side by side. Do the same in Meta Ads Manager if a second platform is in play, and blend the two into one true CAC rather than looking at either platform in isolation, since a single-platform view will understate real cost the moment volume is split across channels.
Then overlay the spend line against the CAC line on the same chart. This is the step that actually separates a real efficiency gain from a managed number. A rising CAC masked by rising spend reads completely differently than a rising CAC on flat spend, and a flat CAC on falling spend is the pattern worth the closest look of all.
One more check worth doing before trusting any of this: sanity-test the platform’s own conversion counts against actual booked-patient records for at least a couple of sample months. This is really a preview of Dimension 3 (Attribution Integrity) later in this series, but it matters here too. A beautiful trend built on inflated platform conversion counts isn’t a beautiful trend at all.
Scoring It
The framework grades this dimension 1 to 5, from CAC/CPL flat or improving across primary service lines at the top end, down to a patient acquisition cost trend that’s actively deteriorating with no credible plan to fix it at the bottom. The two Hard Flags worth knowing before you start: figures that can’t be reconciled against actual spend and closed-patient data, and “improved” efficiency that’s actually a lead-quality collapse in disguise, where CPL drops but close rate or show rate falls just as fast or faster.
That second one catches people. A falling CPL feels like good news until you check what’s actually converting.
Why It Matters for the Deal, Not Just the Marketing Report
A deteriorating patient acquisition cost trend isn’t a marketing footnote. It’s a direct claim on forward EBITDA. If it costs more to hold flat patient volume next year than it did this year, that gap gets absorbed somewhere, either compressed margin or a bigger opex line than the trailing model assumed. This dimension is also where the add-back conversation gets interesting: was marketing spend running at a sustainable level, or was it quietly under-invested in the months before the sale to flatter the number a buyer is about to pay a multiple on.
This is Dimension 1 of 7 in the Patient Marketing Diligence Framework, a standard for evaluating whether a healthcare target’s patient acquisition is built to last or bought to look good for a sale.
Get the full framework: all 7 dimensions, complete scoring criteria, evidence sourcing, and red flag triggers, delivered free.